摘要
1名80岁原发性血小板增多症女性患者,给予羟基脲0.5g口服,3次/d,灯盏花素50mg静脉滴注,1次/d,第4天羟基脲加量至1.0g,3次/d。用药5d后患者出现胸腹部淡红色皮疹,瘙痒难忍。停用灯盏花素,给予抗过敏治疗,因患者PLT已由1120×109/L降至489×109/L,羟基脲减量至0.5g,3次/d。1周后,患者皮疹明显加重,融合呈大片,迁延至腰背、双髋及四肢。遂停用羟基脲,继续给予抗过敏治疗,皮疹逐渐消退。以后给予灯盏花素静脉滴注,未再出现皮疹。
An 80-year-old woman with primary thrombocytosis received orally hydroxycarbamide 0. 5 g thrice daily and Ⅳ breviscapine 50 mg once daily. On day 4, the dosage of hydroxycarbamide was then increased to 1.0 g thrice daily. After 5 days of treatment, the patient developed reddish skin rash on her chest and abdomen, with unbearable pruritus. Breviscapine was discontinued, and she was given anti-anaphylaxis therapy. And the dosage of hydroxycarbamide was decreased to 0. 5 g thrice daily because her platelet count had declined from 1 120 × 10^9/L to 489× 10^9/L. One week later, the patient＇s skin rash was markedly aggravated and fused to big patchy erythema, extending to the lumbus, back, hip, and limbs. Hydroxycarbamide was discontinued, and anti-anaphylaxis therapy was continued. The patient＇s skin rash resolved gradually. Afterward, she was treated with Ⅳ breviscapine,and the skin rash did not recur.
出处
《药物不良反应杂志》
2007年第6期437-438,共2页
Adverse Drug Reactions Journal
关键词
羟基脲
皮疹
hydroxycarbamide
skin rash
